BSEAGM/EGM2d ago · 22 Sept 2026, 10:13 pm

Venmax Drugs and Pharmaceuticals Limited has informed exchange about the meeting of equity shareholders of the Company pursuant to the order passed by Hon. NCLT, Hyderabad bench II in respect of Scheme of Amalgamation of Hatri Pharma Private Limited with Venmax Drugs and Pharmaceuticals Limited.

Venmax Drugs and Pharmaceuticals Ltd · 531015

✦ AI SummaryM&A

Venmax Drugs and Pharmaceuticals Ltd has informed the exchange about the meeting of equity shareholders of the Company pursuant to the order passed by Hon. NCLT, Hyderabad bench II in respect of Scheme of Amalgamation of Hatri Pharma Private Limited with Venmax Drugs and Pharmaceuticals Limited.

Analysis Scores

Earnings Impact5/10
Growth Catalyst6/10
Governance Concern2/10
Regulatory Risk4/10
Balance Sheet Risk3/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Venmax Drugs and Pharmaceuticals Ltd - 531015 - NCLT Conveying Shareholder Meeting On October 24, 2026 At 12.30 P.M.

Attachments (1)

📄

e16d8c8e-9895-4021-9d59-e928b8cee2c1.pdf

pdf

Download →
View document text
September 22, 2026 General Manger BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001. Scrip Code: 531015 Sub: Disclosure under Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/ Madam, In furtherance to our intimation dated September 8, 2026, and further in continuation of intimation regarding the Hon'ble National Company Law Tribunal ("NCLT") had, vide its Order dated September 7, 2026 passed directions in relation to the Scheme of Arrangement in the nature of Merger of Mis Hatri Pharma Private Limited ('Transferor Company") and Mis Venmax Drugs and Pharmaceuticals Limited ("Transferee Company") and their respective Shareholders("Scheme") under Section 230 - 232 and other applicable provisions of the Companies Act, 2013 ("the Act") and Rules framed thereunder, this is to infonn hereby as under: 1. By and under the Order dated September 7, 2026 ("NCL T Order"), the Hyderabad Bench-11 of the Hon'ble NCLT has, inter alia, directed the Meeting of Equity Shareholders of the Transferee Company ("Meeting") for the purpose of considering, and if thought fit, approving with or without modifications, the proposed Scheme, in terms of the NCLT Order. 2. In pursuance of the said NCLT Order and as directed therein and in compliance with the applicable provisions of the Act and Rules framed thereunder and SEBI LODR Regulations, further notice is hereby given that a Meeting of Equity Shareholders of the Transferee Company are scheduled to be convened As per the directions of the Hon 'ble National Company Law Tribunal, Hyderabad Bench - II, the meeting shall be conducted through Video Conferencing or Other Audio Visual Means, at registered office of the Transferee Company situated at Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad - 500009, Telangana on Saturday, October 24, 2026 at 12:30 P.M. (1ST), at which time the Equity Shareholders are requested to attend the Meeting. Reg Office: Sy. No. 115, Brig Sayeed Road,-Hanumanji Colony, Bowenpally, Picket, Hyderabad - 500009 CIN: l24230TG1988PLC009102 GSTIN: 36AAACY1073C3ZM E-mail: venmaxdrugs@gmail.com 3. Copy of the Notice and Statement under Sections 230 and 232 read with Section 102 and other applicable provisions of the Act and Rule 6 of the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016 ("CAA Rules") along with all Annexures to the Statement ("Notice") can be accessed or downloaded from the website of the Company at www.venmaxdrugs.com website of the Bombay Stock Exchange www.bseindia.com and website ofCDSL at www.evotingindia.com. 4. The Notice is also being sent through electronic mode to those Equity Shareholders whose e mails are registered/ available with the Company and/or RTA / Depositories. 5. Further, we enclose herewith the Notice and Explanatory Statement (excluding the Annexures referred therein) convening the aforesaid Meeting. Yours faithfully, ,, I Managing Director DIN:02906370 Encl: as above .........- -------------------------------------------------------------------------------------..- ------------------------------ Reg Office: Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowen pally, Picket, Hyderabad - 500009 CIN: l24230TG1988PLC009102 GSTIN: 36AAACY1073C3ZM E-mail: venmaxdrugs@gmail.com HON'BLE NATIONAL COMPANY LAW TRIBUNAL CONVENED MEETING OF THE EQUITY SHAREHOLDERS VENMAX DRUGS AND PHARMACEUTICALS LIMITED (CIN: L24230TG1988PLC009102) REGD OFF: SY. NO. 115, BRIG SAYEED ROAD, HANUMANJI COLONY, BOWENPALLY, PICKET, HYDERABAD, SECUNDERABAD, TELANGANA -500009, INDIA EMAIL: venmaxdrugs@gmail.com, WEBSITE: www.venmaxdrugs.com DAY SATURDAY DATE 24TH DAY OF OCTOBER, 2026 TIME 12:30 P .M. (12:30 HOURS) THROUGH VIDEO CONFERENCING OR OTHER AUDIO-VISUAL MODE/ MEANS, AT THE REGISTERED OFFICE: SY. NO. 115, BRIG SAYEED VENUE ROAD, HANUMANJI COLONY, BOWENPALLY, PICKET, HYDERABAD -500009, TELANGANA VENMAX DRUGS AND PHARMACEUTICALS LIMITED (CIN: L24230TG1988PLC009102) REGD OFF: SY. NO. 115, BRIG SAYEED ROAD, HANUMANJI COLONY, BOWENPALLY, PICKET, HYDERABAD, SECUNDERABAD, TELANGANA-500009, INDIA EMAIL: [venmaxdrugs@gmail.com], WEBSITE: [www.venmaxdrugs.com] NOTICE OF THE NATIONAL COMPANY LAW TRIBUNAL CONVENED MEETING OF THE EQUITY SHAREHOLDERS OF THE COMPANY CONTENTS PAGE NO. Notice of the Tribunal convened meeting of the Equity Shareholders of 1) 4-18 the Company. Explanatory statement under Section 102 read with sections 230 to 232 and other applicable provisions of the Companies Act, 2013 and details 2) 19-52 & information as required under Rule 6 of the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016. 3) Form of Proxy 53-55 4) Attendance Slip 56-57 5) Route map of the venue of the Meeting 58 Copy order dated 07.09.2026 passed by Hon'ble NCLT, Hyderabad Annexed bench pursuant to which the meeting is to be convened Separately Scheme of Amalgamation of Hatri Pharma Private Limited (Transferor Company) with Venmax Drugs and Pharmaceuticals Limited Annexed (Transferee Company) and their respective Shareholders and Creditors Separately (Scheme). Valuation Report dated 12.11.2025, provided by Mr. Gopavarapu Murali Annexed Reddy, FCA, Registered Valuer (Securities or Financial Assets). Separately Fairness Opinion on the Valuation Report dated 12.11.2025, obtained Annexed 9) from Finshore Management Services Limited, SEBI Registered Category Separately I Merchant Banker. Complaints Report dated 25.04.2026, as submitted by the Company to Annexed BSE Limited. Separately Observation Letter issued by BSE Limited (BSE) dated 15.05.2026 of May, Annexed 2026. Separately Information pertaining to Hatri Pharma Private Limited (unlisted Annexed 12) Transferor Company) in the format of Abridged Prospectus dated Separately 12.11.2025. CONTENTS PAGE NO. Report adopted by the Board of Directors of the Transferee Company Annexed 13) explaining the effect of Scheme on key managerial personnel, promoters Separately and non-promoter Shareholders. Report adopted by the Board of Directors of the Transferor Company, Annexed 14) explaining the effect of Scheme on key managerial personnel, promoters Separately and non-promoter Shareholders. Audited financial statements of the Transferee Company for the last Annexed 15) three financial years & Unaudited financial Results for the Quarter Separately ended June 30, 2026. Audited financial statements of the Transferor Company for the last Annexed 16) three financial years & Unaudited financial Results for the Quarter Separately ended June 30, 2026. A Certificate issued by statutory auditor Confinning the Accounting Annexed treatment under the Scheme for the Transferee Company. Separately A Certificate issued by statutory auditor Confinning the Accounting Annexed treatment under the Scheme for the Transferor Company. Separately A Copy of the Board Resolution passed by the board of directors of the Annexed Transferee Company approving the Scheme. Separately A Copy of the Board Resolution passed by the board of directors of the Annexed Transferor Company approving the Scheme. Separately Pre Scheme and Post Scheme Share Holding Pattern of the Transferee Annexed Company Separately BEFORE THE HON'BLE NATIONAL COMPANY LAW TRIBUNAL, HYDERABAD BENCH-II CA (CAA) NO. 30/230/HDB/2026 IN THE MATTER OF COMPANIES ACT, 2013 (18 of 2013) IN THE MATTER OF SECTIONS 230TO 232 OF THE COMPANIES ACT, 2013 IN THE MATTER OF SCHEME OF AMALGAMATION BETWEEN HAT RI PHARMA PRIVATE LIMITED (TRANSFEROR COMP ANY) VENMAX DRUGS AND PHARMACEUTICALS LIMITED (TRANSFEREE COMPANY) THEIR RESPECTIVE SHAREHOLDERS AND CREDITORS Venmax Drugs and Pharmaceuticals Limited, a Company incorporated under the provisions of Companies Act, 1956, bearing CIN: L24230TG1988PLC009102 and having its registered office situated at Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad, Secunderabad, Telangana- 500009, India .... Applicant/ Trans [Showing first 8,000 characters — download PDF for full document]